Form 4: Marker Therapeutics CEO Granted Stock Options

Marker Therapeutics, Inc. CEO Juan Vera was granted 250,000 employee stock options with an exercise price of $0.9877.

Summary

• Juan Vera, Chief Executive Officer and Director of Marker Therapeutics, Inc. (MRKR), was granted 250,000 employee stock options.
• The options have an exercise price of $0.9877 per share, which was the closing price on the grant date.
• The grant date for these options was October 31, 2025.
• One-fourth of the shares will vest on the first anniversary of the grant date, with the remaining shares vesting in equal annual installments over the second, third, and fourth anniversaries.
• Vesting is contingent upon Mr. Vera's continued performance of services to the company through the respective vesting dates.
• The options have an expiration date of October 31, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to the CEO is a standard executive compensation practice, aligning management interests with long-term shareholder value. It does not reflect on the company's immediate financial performance.

Positives

• The grant of employee stock options to the CEO aligns his long-term financial interests with those of the shareholders, incentivizing sustained performance and value creation.

Negatives

• No direct negatives are presented in this filing, which reports a standard executive compensation event.

Risks

• No specific risks related to the company's operations or financial health are mentioned in this Form 4 filing, which focuses solely on an insider transaction.

Future Outlook

The granted options will vest over a four-year period, with one-fourth vesting on the first anniversary of the grant date and the remainder vesting in equal annual installments over the second, third, and fourth anniversaries, contingent on continued service.

Industry Context

The grant of stock options is a common form of executive compensation in the biotechnology and pharmaceutical industries, used to attract, retain, and incentivize key leadership by linking their compensation to the company's long-term stock performance.

Comparison to Industry Standards

• Not applicable as this filing reports an individual insider transaction, not company-wide performance or project results that would typically be compared to industry benchmarks.

Related Party Transactions

• The grant of 250,000 employee stock options to Juan Vera, the Chief Executive Officer and a Director, constitutes a related-party transaction as part of his executive compensation package under the Company's 2020 Omnibus Stock Ownership Plan.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of CEO's interests with long-term shareholder value.
• Employees (CEO): Direct benefit through equity compensation, providing an incentive for continued service and performance.

Next Steps

• The options will begin to vest on the first anniversary of the grant date (October 31, 2026), with subsequent vesting occurring annually over the following three years.

Key Dates

Keywords

Marker Therapeutics, MRKR, Juan Vera, Stock Options, CEO, Insider Transaction, Form 4, Equity Compensation, Vesting